Pay in 4 interest-free payments of $5.65 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
An update literature review in 2022 (search dates: 06/2013 01/2021) identified 63 studies, 53 of which were added to the evidence base
Currently, there are four main treatments propelling this market forward: Ozempic and Wegovy (semaglutide: a GLP-1 agonist, developed by Novo Nordisk) Mounjaro and Zepbound (tirzepatide: a dual agonist targeting both GLP-1 and GIP (Gastric inhibitory polypeptide) receptors, developed by Eli Lilly) These medications are administered subcutaneously with the assistance of injection pens
Improvements in glycemic parameters and quality of life measures were also observed
International Journal of Molecular Sciences, 2020
We'll build a treatment plan tailored to your goals
US$ 21.71
US$ 25.20
US$ 24.58
US$ 24.11
US$ 23.56
